CLDN5 expression has been shown to be reduced in squamous cell carcinomas of the lung (Akizuki et al., 2017), cervical cancer (Zhu et al., 2015), hepatocellular carcinoma (Sakaguchi et al., 2008), oral squamous cell carcinoma (Phattarataratip and Sappayatosok, 2016), breast cancer (Escudero-Esparza et al., 2012), and pancreatic cancer (Jakab et al., 2011). This evidence concerns the gene CLDN5 and hepatocellular carcinoma.